KB-1032

lemzoparlimab

12065

Background of lemzoparlimab

The approach of blocking CD47 with SIRPa-Fc or anti-CD47 antibodies is showing promise as a cancer treatment by inhibiting the 'do not eat' signal and promoting phagocytosis. However, this method is associated with hematological toxicities, particularly anemia and thrombocytopenia. Lemzoparlimab, also known as TJ011133 or TJC4, is a fully human IgG4 antibody targeting CD47 with a unique binding epitope and the advantage of sparing red blood cells, potentially distinguishing it from other CD47-targeting therapies.

Specifications

Catalog Number	KB-1032
Antibody Name	lemzoparlimab
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P
Target	CD47
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA\|FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results.
A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results.